Literature DB >> 24129628

Feasibility and outcome of CT-guided lung biopsy in patients with hematological diseases and suspected fungal pneumonia.

Sanjeev Kumar Sharma1, Suman Kumar, Avinash Kumar Singh, Tulika Seth, Pravas Mishra, Manoranjan Mahapatra, Sanjay Sharma, Seema Tyagi, Immaculata Xess, Ruma Ray.   

Abstract

INTRODUCTION: Fungal pneumonia is a major cause of morbidity and mortality in immunocompromised patients with hematological diseases. This study is aimed to evaluate the feasibility and outcome of computed tomography (CT) guided lung biopsy or fine needle aspiration cytology (FNAC) in the diagnosis of fungal pneumonia in patients with hematological diseases.
METHODOLOGY: Seven hundred and seventy six consecutive patients with febrile neutropenia were evaluated prospectively over the period of three years. Patients with suspected fungal pneumonia, based on typical CT scan findings, were considered for lung biopsy.
RESULTS: Of the 776 patients evaluated for fever, 235 (30.3%) showed CT scan findings consistent with fungal pneumonia. Of the 235 patients, CT-guided lung biopsy/FNAC was recommended for 178 patients but could be performed in only 34 (19.1%) patients. Fungal pneumonia was proven in 15 (44%) out of 34 patients (aspergillus in 12; mucormycosis in 3 patients). Lung biopsies could not be performed for a number of reasons. These included thrombocytopenia, nodules being too small, infection improving with empiric treatment and patient recovering clinically, and the patient being too sick to undergo intervention. The median absolute neutrophil count (ANC) of patients at the time of lung biopsy was 0.41 x 10⁹/l in patients whose lung biopsy/FNAC showed fungal pneumonia, compared to 2.10 x 10⁹/l in patients whose biopsy/FNAC showed necrotizing pneumonitis.
CONCLUSION: CT-guided lung biopsy/FNAC can allow the definitive diagnosis of fungal pneumonia in selected patients with various hematological diseases and should be attempted whenever clinically indicated and radiologically feasible.

Entities:  

Mesh:

Year:  2013        PMID: 24129628     DOI: 10.3855/jidc.2823

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  6 in total

1.  Invasive Fungal Infections in Acute Promyelocytic Leukemia on Dual Differentiating Agents: Real World Data.

Authors:  Uday Yanamandra; Parathan Karunakaran; Alka Khadwal; Gaurav Prakash; Deepesh Lad; Shano Naseem; Neelam Varma; Arunaloke Chakrabarti; Subhash Varma; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2017-10-26       Impact factor: 0.900

2.  Computed tomography-guided lung biopsy for molecular tests: a meta-analysis.

Authors:  Jian-Hua Zhang; Feng-Fei Xia; Xiao-Shan Yang; Yu Li
Journal:  Kardiochir Torakochirurgia Pol       Date:  2022-06-29

3.  Pulmonary Mucormycosis in a Patient with Systemic Lupus Erythematosus: A Diagnostic and Treatment Challenge.

Authors:  Hung-Chang Hung; Gang-Yu Shen; Shiuan-Chih Chen; Kai-Jieh Yeo; Shih-Ming Tsao; Meng-Chih Lee; Yuan-Ti Lee
Journal:  Case Rep Infect Dis       Date:  2015-06-22

4.  Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience.

Authors:  Cornelia Lass-Flörl; Maria Aigner; David Nachbaur; Stephan Eschertzhuber; Brigitte Bucher; Christian Geltner; Romuald Bellmann; Michaela Lackner; Dorothea Orth-Höller; Reinhard Würzner; Günter Weiss; Bernhard Glodny
Journal:  Infection       Date:  2017-09-27       Impact factor: 3.553

Review 5.  Acute respiratory failure in immunocompromised adults.

Authors:  Elie Azoulay; Djamel Mokart; Achille Kouatchet; Alexandre Demoule; Virginie Lemiale
Journal:  Lancet Respir Med       Date:  2018-12-07       Impact factor: 30.700

Review 6.  Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.

Authors:  Valliappan Muthu; Ritesh Agarwal; Atul Patel; Soundappan Kathirvel; Ooriapadickal Cherian Abraham; Ashutosh Nath Aggarwal; Amanjit Bal; Ashu Seith Bhalla; Prashant N Chhajed; Dhruva Chaudhry; Mandeep Garg; Randeep Guleria; Ram Gopal Krishnan; Arvind Kumar; Uma Maheshwari; Ravindra Mehta; Anant Mohan; Alok Nath; Dharmesh Patel; Shivaprakash Mandya Rudramurthy; Puneet Saxena; Nandini Sethuraman; Tanu Singhal; Rajeev Soman; Balamugesh Thangakunam; George M Varghese; Arunaloke Chakrabarti
Journal:  Lancet Infect Dis       Date:  2022-04-04       Impact factor: 71.421

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.